AstraZeneca EPS beats by $0.17, beats on revenue; reaffirms earnings guidance for the full year
AstraZeneca EPS beats by $0.17, beats on revenue; reaffirms earnings guidance for the full year
SeekingAlpha
0 shares
1 views
You might like
Related news coverage
-
Walmart EPS beats by $0.06, beats on revenue, raises full-year guidance
SeekingAlpha
-
New Gold EPS beats by $0.01, misses on revenue; on track to meet full year production guidance
SeekingAlpha
-
Wix.com EPS beats by $0.20, beats on revenue; updates full year guidance
SeekingAlpha
-
Him & Hers Health EPS in-line, beats on revenue; issues Q4 and full year guidance
SeekingAlpha
Advertisement
More coverage
-
D. R. Horton EPS beats by $0.31, beats on revenue; issues full year guidance
SeekingAlpha
-
First Advantage EPS beats by $0.09, beats on revenue; boosts full year guidance
SeekingAlpha
-
Magna International EPS misses by $0.16, beats on revenue; updates full year guidance
SeekingAlpha
-
Pembina Pipeline EPS beats by C$0.32, beats on revenue; reaffirms full year guidance
SeekingAlpha